Entering text into the input field will update the search result below

Recommended For You

Comments (12)

Interesting article, thanks.
jstratt profile picture
I will add a few comments regarding AMGN which I feel is the best investment in biotech at this moment and one of the best investments in the S&P500.

- 14.7 PE on 2015 EPS est
- 10%+ growth projected for 5 years
- 4 new drugs this year launched
- Repatha has the potential to be a huge HR (CVS estimates $100 bil sales PCSK9)
- AMGN continuing to cut costs and reduce overhead raising profit level
- Older drugs doing better than expected
- 14.5 PE based on my 2015 est of $9.90
- 2.2% dividend likely to get significant bump (est 10%)
- share price getting hit by IBB/ETF selling rather than on AMGN's merits
All very good points.
This one has a much lower risk than other biotechs.
Ideally for a retired person, this is a very good choice.
Stephen Barnes profile picture
not to mention huge sales that will come from Kyprolis recent approval in US and EU. I would say $2 billion in sales in 2 years. this will offset of the lost sales from biosimilar and Repatha sales will be gravy on top.
Synthroid is not a cancer treatment. It's thyroid hormone. People with autoimmune thyroid disease, hypothyroidism, and those that have had their thyroid removed take it. Thyroid hormone plays a role in many systems of the body.
farstud profile picture
Yup. Author probably was confused. Sure they'll put you on Levo after a total thyroidectomy for thyroid ca. Certainly doesn't make it a 'cancer drug'.
Not sure if I read it correctly.
Crestor sales of $21.5 Billion.
Absolutely not true. Not even half of that.
Synthroid sales were the highest in terms of scripts and not $s.
In terms of $ sales Humira tops the list.($12.5 Billion in 2014)
Sovaldi came second in 2014 with 410.3 Billion.
The best product that Amgen has with the highest potential sales (in the future ) is for osteoporosis.( Romosozumab).
(Unlike all the other products for OP the Amgen product works on the Osteoblast v/s Oseoclast )
As it gets hammered daily,Thanks Hillary!
MineMan profile picture
Hillary makes a comment about a crook and Pharms charging exorbitant prices for new drugs. And the whole macro market dip makes her the scapegoat. NOT THE PHARMs that make the American taxpayer (Medicare), pay for the high cost of RXs. Fair is fair, let Medicare negotiate RX prices.
She used one specific case and saw it as an opportunity to gain popularity by knocking the entire industry.She will not be able to accomplish her outlined plan even in the long shot that she was elected,but I am sure she knew the implications of her comments in the short term.
Isn't the market for CVD pretty well cornered? What does Dezima offer that hasn't already been marketed?
24 Sep. 2015
Good read most interesting, greater is coming!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About AMGN Stock

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on AMGN

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.